Skip to main content
Year archive

ENTROPY NEURODYNAMICS LIMITED — 2020 filings

All 69 regulatory filings released by ENTROPY NEURODYNAMICS LIMITED (ENP) in 2020, sourced directly from the official regulator.

69 Filings
2020 Period
2020 filings (69)
Filing Released Lang
Response to ASX Price and Volume Query 3 pages 528.6KB
Regulatory Filings
2020-12-29 English
Change of Director's Interest Notice 2 pages 167.1KB
Director's Dealing
2020-12-22 English
Shareholder Update 8 pages 197.7KB
Regulatory Filings
2020-12-21 English
Appendix 2A 15 pages 274.8KB
Regulatory Filings
2020-12-17 English
Release of Securities from 24 Month Escrow 2 pages 151.3KB
Share Issue/Capital Change
2020-12-10 English
Appendix 2A 15 pages 302.1KB
Capital/Financing Update
2020-12-01 English
Cleansing Notice 1 page 174.1KB
Share Issue/Capital Change
2020-12-01 English
Change of Director's Interest Notice 2 pages 189.2KB
Director's Dealing
2020-12-01 English
Results of Meeting 2 pages 195.0KB
Declaration of Voting Results & Voting Rights Announcements
2020-11-29 English
Updated Quarterly Activities Report 6 pages 319.1KB
Interim / Quarterly Report
2020-11-12 English
Change of Registered Office Address 1 page 77.8KB
Regulatory Filings
2020-11-12 English
Exopharm to Present at Key Exosome Industry Event 35 pages 2.3MB
Investor Presentation
2020-11-10 English
Addendum to Notice of Annual General Meeting 5 pages 147.2KB
AGM Information
2020-11-09 English
Letter to Shareholders - Addendum to Notice of AGM 2 pages 160.5KB
AGM Information
2020-11-09 English
Change of Director's Interest Notice 2 pages 248.5KB
Director's Dealing
2020-11-09 English
Change of Director's Interest Notice 2 pages 247.3KB
Director's Dealing
2020-11-09 English
Change in substantial holding 2 pages 1.7MB
Regulatory Filings
2020-11-09 English
Appendix 2A 15 pages 253.6KB
Regulatory Filings
2020-11-08 English
Appendix 2A 15 pages 253.5KB
Capital/Financing Update
2020-11-08 English
Appendix 2A 15 pages 253.7KB
Regulatory Filings
2020-11-08 English
Appendix 3G 13 pages 263.9KB
Share Issue/Capital Change
2020-11-08 English
Appendix 3G 12 pages 259.6KB
Share Issue/Capital Change
2020-11-08 English
Cleansing Notice 1 page 108.3KB
Capital/Financing Update
2020-11-08 English
Results of Meeting 3 pages 375.4KB
Declaration of Voting Results & Voting Rights Announcements
2020-10-28 English
Notice of Annual General Meeting/Proxy Form 18 pages 939.0KB
AGM Information
2020-10-28 English
Letter to Shareholders - Annual General Meeting 1 p
AGM Information
2020-10-28 English
September Quarterly Report and Appendix 4C 10 pages 535.2KB
Interim / Quarterly Report
2020-10-26 English
Plexoval II First Dosing and $2.1m R&D Rebate Received 3 pages 805.2KB
Capital/Financing Update
2020-10-21 English
Annual General Meeting Date and Director Nominations 1
AGM Information
2020-10-05 English
Notice of Extraordinary General Meeting/Proxy Form 27 pages 1.6MB
Proxy Solicitation & Information Statement
2020-09-23 English
Letter to Shareholders 3 pages 230.3KB
Proxy Solicitation & Information Statement
2020-09-23 English
Shareholder Update 19 pages 2.2MB
Investor Presentation
2020-09-17 English
Change in substantial holding 2 pages 88.7KB
Major Shareholding Notification
2020-09-16 English
EX1 appoints Manufacturing Expert and Corporate Advisor 3 pages 226.6KB
Board/Management Information
2020-09-14 English
Proposed issue of Securities - EX1 7 pages 33.6KB
Capital/Financing Update
2020-09-14 English
Annual Report to Shareholders 59 pages 4.7MB
Regulatory Filings
2020-09-13 English
Cleansing Notice 1 page 162.3KB
Regulatory Filings
2020-09-08 English
Appendix 2A 15 pages 253.7KB
Regulatory Filings
2020-09-07 English
Exopharm raises $10m in well supported Placement 3 pages 131.7KB
Capital/Financing Update
2020-08-26 English
Proposed issue of Securities - EX1 5 pages 28.2KB
Capital/Financing Update
2020-08-26 English
Proposed issue of Securities - EX1 6 pages 31.5KB
Capital/Financing Update
2020-08-26 English
Appendix 4E and Annual Financial Report FY 2020 63 pages 2.0MB
Annual Report
2020-08-25 English
Corporate Governance Statement and Appendix 4G 27 pages 439.9KB
Governance Information
2020-08-25 English
Investor Presentation 23 pages 1.4MB
Capital/Financing Update
2020-08-20 English
Trading Halt 2 pages 550.4KB
Capital/Financing Update
2020-08-20 English
Shareholder Update 5 pages 245.4KB
Regulatory Filings
2020-08-18 English
Top 20 securityholders 3 pages 135.2KB
Major Shareholding Notification
2020-08-12 English
June Quarterly Report and Appendix 4C 9 pages 324.7KB
Interim / Quarterly Report
2020-07-29 English
Shareholder Update 17 pages 1.4MB
Investor Presentation
2020-07-21 English
Monsoon Communications Morning Twilight Briefing Webinar 2 pages 112.9KB
Investor Presentation
2020-07-20 English
Company Secretary and services update 2 pages 112.5KB
Board/Management Information
2020-06-15 English
Added IP empowers Exopharms engineered exosome pipeline 4 pages 305.2KB
Regulatory Filings
2020-06-11 English
Top 20 securityholders 3 pages 166.0KB
Major Shareholding Notification
2020-06-11 English
Shareholder Update 6 pages 215.6KB
Regulatory Filings
2020-05-27 English
Plexaris product engineered to deliver anti-cancer drug 4 pages 191.7KB
Capital/Financing Update
2020-05-24 English
March Quarterly Report and Appendix 4C 11 pages 512.7KB
Interim / Quarterly Report
2020-04-23 English
PLEXOVAL I study disrupted by the Covid-19 response 2 pages 207.3KB
Regulatory Filings
2020-03-31 English
Shareholder Update 3 pages 214.9KB
Capital/Financing Update
2020-03-25 English
Investor Deck 27 pages 2.0MB
Investor Presentation
2020-03-04 English
Statement Clarification 2 pages 227.6KB
Regulatory Filings
2020-02-23 English
Cevaris testing shows positive results in bladder control 4 pages 262.4KB
Regulatory Filings
2020-02-19 English
Appendix 4D and Interim Financial Report 22 pages 759.3KB
Interim / Quarterly Report
2020-02-19 English
Cevaris testing shows positive results in models of ED 4 pages 223.3KB
Regulatory Filings
2020-02-18 English
Erectile Dysfunction a Potential Target for Exosomes 6 pages 121.3KB
Regulatory Filings
2020-02-13 English
Independent Plexaris and Cevaris testing 6 pages 123.9KB
Regulatory Filings
2020-02-11 English
Shareholder Update 4 pages 124.3KB
Regulatory Filings
2020-02-09 English
Investor Deck 26 pages 1.8MB
Investor Presentation
2020-02-04 English
December Quarterly Report and Appendix 4C 10 pages 313.1KB
Interim / Quarterly Report
2020-01-28 English
First Dosing in PLEXOVAL Exosome Wound Healing Human Study 3 pages 107.1KB
Capital/Financing Update
2020-01-27 English